Bessemer Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $349K | Sell |
2,776
-3,984
| -59% | -$501K | ﹤0.01% | 945 |
|
|
2025
Q1 | $747K | Sell |
6,760
-13,893
| -67% | -$1.54M | ﹤0.01% | 780 |
|
|
2024
Q4 | $2.82M | Sell |
20,653
-1,113
| -5% | -$152K | ﹤0.01% | 583 |
|
|
2024
Q3 | $2.51M | Buy |
21,766
+20,168
| +1,262% | +$2.32M | ﹤0.01% | 612 |
|
|
2024
Q2 | $220K | Hold |
1,598
| – | – | ﹤0.01% | 990 |
|
|
2024
Q1 | $221K | Sell |
1,598
-8
| -0.5% | -$1.11K | ﹤0.01% | 999 |
|
|
2023
Q4 | $212K | Buy |
1,606
+56
| +4% | +$7.39K | ﹤0.01% | 1027 |
|
|
2023
Q3 | $175K | Sell |
1,550
-64
| -4% | -$7.23K | ﹤0.01% | 1061 |
|
|
2023
Q2 | $153K | Buy |
1,614
+130
| +9% | +$12.3K | ﹤0.01% | 1118 |
|
|
2023
Q1 | $150K | Buy |
1,484
+1,142
| +334% | +$115K | ﹤0.01% | 970 |
|
|
2022
Q4 | $42K | Buy |
342
+302
| +755% | +$37.1K | ﹤0.01% | 1180 |
|
|
2022
Q3 | $4K | Sell |
40
-11
| -22% | -$1.1K | ﹤0.01% | 1784 |
|
|
2022
Q2 | $5K | Sell |
51
-163
| -76% | -$16K | ﹤0.01% | 1527 |
|
|
2022
Q1 | $20K | Buy |
214
+4
| +2% | +$374 | ﹤0.01% | 1243 |
|
|
2021
Q4 | $18K | Sell |
210
-78
| -27% | -$6.69K | ﹤0.01% | 1294 |
|
|
2021
Q3 | $28K | Buy |
288
+125
| +77% | +$12.2K | ﹤0.01% | 1167 |
|
|
2021
Q2 | $16K | Sell |
163
-829
| -84% | -$81.4K | ﹤0.01% | 1267 |
|
|
2021
Q1 | $96K | Buy |
+992
| New | +$96K | ﹤0.01% | 888 |
|
|
2019
Q1 | – | Sell |
-155
| Closed | -$11K | – | 1898 |
|
|
2018
Q4 | $11K | Hold |
155
| – | – | ﹤0.01% | 1635 |
|
|
2018
Q3 | $19K | Buy |
+155
| New | +$19K | ﹤0.01% | 1476 |
|
|
2016
Q1 | – | Sell |
-149
| Closed | -$8K | – | 1600 |
|
|
2015
Q4 | $8K | Buy |
+149
| New | +$8K | ﹤0.01% | 1274 |
|
|
2015
Q1 | – | Sell |
-1,500
| Closed | -$34K | – | 1546 |
|
|
2014
Q4 | $34K | Hold |
1,500
| – | – | ﹤0.01% | 1010 |
|
|
2014
Q3 | $24K | Buy |
+1,500
| New | +$24K | ﹤0.01% | 990 |
|